ImunofanИмунофан
A synthetic hexapeptide, Arg–Asp–Lys–Val–Tyr–Arg (RDKVYR). Laboratory and clinical studies examined immune markers, wound complications and its use alongside cancer treatment.
What the studies found
Comparison in people · 2009
Imunofan and skin infections in military cadets
- Pyoderma incidence
- 40 vs 133 per 1,000Imunofan versus comparison. The 75-per-group conference report supplies the rates.
- Protection coefficient and effectiveness index
- 69.2% and 3.25Values printed in the journal. Rounded incidence rates yield a slightly different ratio.
- CD4/CD8 ratio at day 28–30
- 1.8 → 1.4 vs 1.6 → 0.9Imunofan versus comparison, based on the paper and conference report.
A 150-cadet comparison reported 40 versus 133 skin infections per 1,000 during observation. CD4/CD8 ratios fell from 1.8 to 1.4 with Imunofan and from 1.6 to 0.9 in the comparison group.
Study notes · methods, sources and limitations
Participants or model 150 male first-year cadets aged 18–21. Imunofan 75, no Imunofan 75, in the same training unit.
Design The authors measured blood markers before dosing and at days 28–30 and tracked purulent skin infections. The companion conference report gives the incidence rates.
Important limitations
- The paper describes random group selection. Allocation concealment and masking are unclear. The matching methods and immune-marker values suggest the conference abstract repeats this sample and the 2014 thesis expands the program. No cohorts are added together.
Military Medical Journal. 2009;330(9). · Publication record
Animal research · 2003
Nociceptive reactions during stimulation of immunity in rats with different individual sensitivities to stress.
- Pain thresholds
- Lower: hyperalgesia reportedMore marked in stress-sensitive rats; no numerical threshold shift supplied
- Open-field behavior
- Active behavior suppressed
Imunofan suppressed active behavior and increased pain sensitivity, with larger hyperalgesia in stress-sensitive rats.
Study notes · methods, sources and limitations
Participants or model 43 male Wistar rats differing in stress sensitivity
Design 43 male Wistar rats; IM Imunofan 10 microliters of 0.005% solution; separate intracerebroventricular experiment.
Important limitations
- Animal route-specific effects cannot predict human adverse-event rates; this translation is not separate replication of the earlier Russian report. Full methods, reporting completeness and independent replication remain to be appraised.
- Values describe this study and its comparison. Unreported effect sizes and missing denominators have not been inferred.
Neuroscience and behavioral physiology · PMID 14635999 · Original journal report
Comparison in people · 2011
Imunofan and mixed herpesvirus infections in Redkin and Lyuboshenko’s 2011 comparison
Study of multiple preparations
- Clinical improvement
- 73.7% versus 57.1%Imunofan-based care versus the pooled thymic-peptide group. Denominators conflict in the paper.
- Fewer, shorter or no recurrences
- 36.8% versus 28.6%Composite reported in Table 2.
- Immunogram normalization
- 85.7% versus 84.3%Table 2. No formal between-group test given for these percentages.
The paper reports clinical improvement in 73.7% with Imunofan-based care versus 57.1% with a pooled thymic-peptide comparison. Immunogram normalization was similar (85.7% versus 84.3%). Allocation followed the order patients presented, and some percentages do not match the stated counts.
More reported outcomes
- Temperature normalization
- 21% versus 14.3%
- Lower antiviral or antibacterial antibody titres
- 31.6% versus 14.3%
- CD3 lymphocytes
- 53.34 ± 1.55% to 65.8 ± 1.70%Within the Imunofan group.Reported p < 0.05
- CD4 lymphocytes
- 31.36 ± 1.29% to 36.95 ± 1.40%Within the Imunofan group.Reported p < 0.05
- Spontaneous IFN-γ
- 23.8 ± 2.47 to 42.13 ± 7.75 pg/mLWithin the Imunofan group.Reported p < 0.05
- Stimulated IFN-γ
- 1,669.7 ± 123.1 to 2,170.6 ± 89.8 pg/mLWithin the Imunofan group.Reported p < 0.05
Study notes · methods, sources and limitations
Participants or model Adults with chronic recurrent infections referred to an immunologist in Omsk in 2010–2011. The methods give 35 patients per group, but list 29 women and 8 men in the Imunofan arm (37) and 25 women and 10 men in the comparison arm (35).
Design The methods list 35 patients per group but also give 29 women and 8 men in the Imunofan arm. Assignment followed order of presentation. Both groups received individualized care. The comparator pooled Thymalin, Thymogen and Tactivin. Lymphocyte markers and IFN-γ were assessed before and after treatment.
Important limitations
- The comparison group pooled Thymalin, Thymogen and Tactivin. The paper gives no drug-specific subgroup outcomes, so the rates cannot establish a difference versus any one preparation. The groups were assigned in order of presentation and differed in average age. Concurrent antimicrobial and immune-active treatment varied by clinical presentation. The Imunofan denominator conflicts within the methods, and Table 2 supplies percentages without event counts or a separate significance test. No systematic adverse-event results were reported.
- The Table 2 percentages are reproduced as published. The paper gives conflicting group sizes and no event counts, and the groups received different care. The IFN-γ and lymphocyte figures are within-group changes.
Public Health of the Far East. 2011;3(49):38–41. · Original journal article
Imunofan in cancer research
- Mammary tumor experiment · 33 mice. At week nine, tumor diameter among mice that developed tumors was 14.1 mm after Imunofan pretreatment versus 6.9 mm with saline (p=0.029). By week 15, the proportion that had developed palpable tumors was 70% versus 83%.
- Breast cancer care · 174 patients. The Samara author abstract reported 20/92 versus 24/82 local postoperative complications. The printed significance claim cannot be reproduced from those counts. The related patent gives two illustrative cases.
- Endometrial cancer · 220 patients. A Tver conference report described 12.7% fewer radiation complications (p<0.05) with adjunctive Imunofan. The abstract gives no raw event counts and may share participants with the earlier Tver journal report.
- Lung cancer surgery · 148 patients. Two Imunofan-containing combinations enrolled 49 people. The authors reported fewer postoperative complications and omitted absolute rates from the abstract.
The patient studies evaluated Imunofan alongside cancer treatment. The effects on tumor growth in people remain unknown.
About Imunofan
Names in this research collection
RDKVYR · Arg-Asp-Lys-Val-Tyr-Arg
Research background
A synthetic RDKVYR hexapeptide with cell, animal and human wound-related research. Historical Thymohexin names have conflicting sequence order.
Autoimmune research: disease-specific findings, immune effects and open questions ↗
Pregnancy and offspring research
The program reports threatened pregnancy loss falling from 41.3% to 19.6% and preterm birth from 8.7% to 4.7%. Imunofan was an adjunct only in the 36-woman middle-risk protocol; these overall results cannot be assigned to Imunofan.
Imunofan-specific effects cannot be isolated: different baseline risks, immunoglobulin exposure, plasmapheresis and historical comparisons confound the program outcomes.
Reported findings and methods ↗ · Pregnancy research: full evidence review and archive ↗
More study findings
Comparison in people · 2014
Imunofan infection prevention across two military training seasons
- Author-calculated pyoderma protection at month 3
- 61.5% autumn, 56.3% winterFrom the author’s treated-versus-comparison incidence calculations.Reported p<0.05
- Skin bactericidal index
- 80–90% vs 60–70%Imunofan versus untreated comparison.Reported p<0.05
The dissertation reports author-calculated protection estimates of 61.5% in autumn and 56.3% in winter at three months. The treated group’s day-28 to day-30 skin bactericidal index was 80–90% compared with 60–70%.
Study notes · methods, sources and limitations
Participants or model 162 Imunofan recipients and 165 comparison participants in the thesis immune-marker table. Other prevention cohorts had separate interventions.
Design The Moscow Military District prevention program followed training cohorts recruited around seasonal peaks. It tracked respiratory and skin illness and assessed blood markers after 28–30 days.
Important limitations
- Season, unit and concurrent prevention measures can influence infection rates. The thesis gives program results and a comparison table, with limited detail on allocation. This appears to extend the 2009 cadet study. The smaller group is excluded from any combined count.
Doctoral dissertation author abstract. Moscow, 2014. Tables 7 and 9. · Publication record
Comparison in people · 2023
Imunofan in risk-stratified obstetric care
- Threatened pregnancy loss
- 41.3% / 19.6%Table’s without/after immunocorrection columns for the n=112 program; not the n=36 Imunofan subgroupTable star: p<0.05
- Preterm birth
- 8.7% / 4.7%Same whole-program columns; raw event denominators not suppliedTable star: p<0.05
- Neonatal morbidity
- 638.0 / 264.0 per 1,000Morbidity rate, not percentage of infants; multiple diagnoses may occurTable star: p<0.05
The program reports threatened pregnancy loss falling from 41.3% to 19.6% and preterm birth from 8.7% to 4.7%. Imunofan was an adjunct only in the 36-woman middle-risk protocol; these overall results cannot be assigned to Imunofan.
More reported outcomes
- Viral transmission
- 54.5% / 18.2%No significance star for this row; narrative significance claims are broader than table notation
- Neutral outcomes
- No reduction in overall gestational complications or spontaneous pregnancy loss; no significant effect on perinatal mortalityExplicit discussion statement on printed p.47
Study notes · methods, sources and limitations
Participants or model 112 women with latent herpesvirus infection: low-risk n=27, renal-inflammatory disease n=36, prior reproductive loss n=49; historical cohorts n=24 and n=42 discussed separately
Design Risk-stratified clinical program compared with earlier protocols; all groups received immunoglobulin, and the highest-risk group also plasmapheresis. Table 1 labels the n=112 dataset Nikitin 2017, although the article was published in 2023. No randomized Imunofan-only comparator.
Important limitations
- Imunofan-specific effects cannot be isolated: different baseline risks, immunoglobulin exposure, plasmapheresis and historical comparisons confound the program outcomes.
- Imunofan-specific effects cannot be isolated: different baseline risks, immunoglobulin exposure, plasmapheresis and historical comparisons confound the program outcomes. The 112 women are not an Imunofan treatment arm. Only the n=36 risk-group protocol explicitly adds it, and subgroup outcomes are not separately supplied. Publication year 2023 is not recruitment year: the outcome table labels these data 2017. No raw outcome counts, confidence intervals or systematic long-term child-safety follow-up were verified. The paper reports important neutral outcomes. Historical exposure does not establish a current indication or safety during pregnancy.
Healthcare of the Far East / Zdravookhranenie Dalnego Vostoka. 2023;(2):43–48 · Original journal publication
Review of earlier studies · 2026
From thymus extracts to synthetic thymomimetics
Study of multiple preparations
- Thymomimetic research
- The authors summarize evidence from different thymic compounds and discuss changes in neutrophil phenotype and function in studies of Imunofan.
The review traces the move from thymus-derived mixtures to defined compounds and summarizes neutrophil phenotypes and functional assays reported for the thymopoietin-derived hexapeptide Imunofan.
Study notes · methods, sources and limitations
Participants or model Review of laboratory and clinical literature on thymic peptides.
Important limitations
- Cell markers, laboratory findings and outcomes from combination care answer different questions. The review does not validate efficacy across thymic peptides.
- Secondary synthesis. No new clinical cohort or pooled effect estimate.
Adaptive Medical Immunology and Public Health Issues. 2026;2(1):6–19. · Narrative review
Comparison in people · 2022
Imunofan after surgery for acute peritonitis in children
- ICU stay in diffuse peritonitis
- 2 (1.0–2.5) versus 4 (3.5–4.0) daysImunofan plus standard care (n = 5) versus standard care (n = 3). Medians and reported intervals.Reported p < 0.05
- CD64-positive neutrophil subset in diffuse disease
- 60.7% to 0.74%Within the Imunofan arm. Standard-care subgroup showed no significant change on this measure.Within-arm p < 0.05
- Time to fever normalization in diffuse disease
- 4 (3.0–4.5) versus 6 (5.5–6.5) daysImunofan plus standard care (n = 5) versus standard care (n = 3).Reported p < 0.05
For diffuse peritonitis, median ICU stay was 2 versus 4 days in groups of 5 and 3 children. The authors also reported changes in neutrophil populations and function. The groups were small and random assignment was not documented.
More reported outcomes
- Drain removal in diffuse disease
- 3 (2–3) versus 5 (4.5–5.0) daysReported p < 0.05
- CD64-negative neutrophil subset in diffuse disease
- 29.6% to 95.97%Within the Imunofan arm. Standard-care endpoint was 40.1%. Healthy reference median was 93.3%.Within-arm p < 0.05
- Actively phagocytosing neutrophils in diffuse disease
- 62% to 71%Within the Imunofan arm.Reported p < 0.05
- Stimulated oxidative-burst assay in local disease
- 7.5% to 17.0% formazan-positive cellsWithin the Imunofan arm. The separate cytochemical index changed from 0.46 to 0.49 (p > 0.05).Reported p < 0.05 for cell percentage
- Local disease: phagocytosis and digestive activity
- Several changes did not reach statistical significanceThe authors report p > 0.05 for the actively phagocytosing cell fraction, digestive activity and particle uptake in the Imunofan arm.
Study notes · methods, sources and limitations
Participants or model 18 children aged 5–12 with acute peritonitis after surgery. Local disease: 7 received Imunofan plus standard care and 3 received standard care. Diffuse disease: 5 and 3, respectively. Another 18 healthy children provided laboratory reference values.
Design In local peritonitis, 7 children received the adjunct and 3 received standard care. In diffuse disease, the groups had 5 and 3 children. Another 18 healthy children provided laboratory reference values. The investigators used blood flow cytometry to measure neutrophil subsets and tested phagocytosis and oxidative-burst activity before and after treatment.
Important limitations
- The clinical groups had only 3–7 children each. The study does not describe random assignment or blinded outcome assessment. The paper reports bowel paresis in 80% of the diffuse comparison group, but lists three patients in that group. The percentage has no reconcilable event count. The related 2022 Effective Pharmacotherapy article repeats the same arm sizes, clinical timings and several marker values. Its patient counts are not added as a separate cohort. Figure 2 prints a concentration unit that conflicts with the product insert. The administered peptide mass is unconfirmed.
- The ICU comparison rests on eight children, and the marker results include changes from baseline. The study does not establish a reliable clinical treatment effect.
Medical Immunology (Russia). 2022;24(3):553–572. · Original journal article, author-shared copy
Laboratory analysis · 2003
Imunofan ranked differently across two antioxidant assays
- Lipid peroxyl radical assay
- Ginseng extract > bursin > cyclobursin > thymopoietin II fragment > Imunofan and glycine
- Aqueous peroxyl and luminol radical assay
- Ginseng extract > thymopoietin II fragment > Imunofan > glycine, cyclobursin and bursin
Imunofan ranked near the bottom in the lipid assay, alongside glycine. It ranked third in the aqueous assay, below ginseng extract and the thymopoietin II fragment.
Study notes · methods, sources and limitations
Participants or model Two cell-free oxidation assays comparing Imunofan, other peptides, glycine and Siberian ginseng extract.
Design One assay measured lipid oxidation in phospholipid liposomes. The other measured luminol oxidation in aqueous solution.
Important limitations
- The abstract gives the order of activity without numerical effect sizes or uncertainty. These cell-free comparisons do not measure antioxidant effects in patients.
Bulletin of Experimental Biology and Medicine. 2003;136(2):155–158. PMID 14631497. · Original laboratory study, indexed abstract
Cited in a dissertation · 2002
Imunofan, Thymalin and levamisole in a historical schizophrenia citation
Study of multiple preparations
- Positive response as quoted in the dissertation
- 53.6% Imunofan, 43.8% Thymalin, 34% levamisoleGroup sizes, definitions and statistical tests are unavailable.
Palko’s dissertation cites positive responses of 53.6% for Imunofan, 43.8% for Thymalin and 34% for levamisole. The original comparison and its response definition have not been verified.
Study notes · methods, sources and limitations
Participants or model Patients described as having treatment-resistant schizophrenia. Group sizes are unavailable in the cited passage.
Important limitations
- Palko attributes the figures to Muzychenko et al. (2002), but the bibliography entry under that attribution lists a paper about milnacipran (Ixel). The passage gives no group sizes, doses, allocation, response definition, statistical tests or harms. The 1998 Thymalin conference report and the Imunofan patent describe different sets of arms. Their methods cannot be assigned to this comparison.
- The bibliography entry points to milnacipran. The percentages are traceable to Palko’s text, but the original comparison has not been verified.
2002 comparison cited in O. L. Palko’s dissertation on myelopeptide immunomodulators. · Secondary dissertation citation
Animal research · 2013
Imunofan pretreatment and mammary tumor growth in mice
- Tumor diameter at week 9 among tumor-bearing mice
- 14.1 mm with Imunofan versus 6.9 mm with saline (p=0.029). The IL-2 group measured 13.9 mm (p=0.092 versus saline).
- Palpable tumors by week 8
- 70% with Imunofan, 73% with IL-2 and 50% with saline.
- Deaths among tumor-bearing mice through week 15
- 100% with Imunofan, 75% with IL-2 and 40% with saline, as reported. The denominators are the animals that developed tumors.
Tumor diameter at week 9 among tumor-bearing mice · 14.1 mm with Imunofan versus 6.9 mm with saline (p=0.029). The IL-2 group measured 13.9 mm (p=0.092 versus saline).
More reported outcomes
- Palpable tumors by week 15
- 70% with Imunofan, 73% with IL-2 and 83% with saline. Earlier detection and faster growth among tumor bearers occurred alongside a lower final proportion with palpable tumors in the treated arms.
Study notes · methods, sources and limitations
Participants or model 33 male A/Sn mice. Imunofan n=10, IL-2 n=11 and saline n=12.
Design One injection before tumor-cell implantation. Imunofan was reported as 0.2 mL of a 1% solution, IL-2 as 1,000 IU, and saline as 0.2 mL of 0.9% NaCl per mouse. Three days later, mice received 500,000 syngeneic mammary tumor cells subcutaneously. Tumor appearance and diameter were tracked weekly through week 15.
Important limitations
- The comparison used a small pre-implantation model. The diameter and mortality comparisons were conditional on developing a tumor. The report gives unadjusted tests at several time points and does not provide evidence on human tumor growth or survival. The report prints a 1% solution without clarifying the formulation or injection route for the pretreatment. The actual peptide mass cannot be confirmed.
Modern High Technologies, 2013, issue 9, p. 54. · Original conference report
Comparison in people · 2004
Imunofan during endometrial cancer treatment and rehabilitation
- Radiation complications
- Reported 12.7% lower with Imunofan (p<0.05). Absolute rates and the denominator for this difference were not supplied.
- Karnofsky performance assessment
- The proportion with high scores was reported as 21.8% higher (p<0.05). Absolute rates and the threshold for a high score were unavailable.
- Mortality and survival
- The authors reported one-year mortality 9.8% lower and a trend toward 8% higher five-year survival. Event counts, uncertainty and an adjusted comparison were unavailable.
Radiation complications · Reported 12.7% lower with Imunofan (p<0.05). Absolute rates and the denominator for this difference were not supplied.
More reported outcomes
- Lymphocyte recovery and tolerability
- Reported about 1.5 times faster lymphocyte recovery (p<0.05). The abstract states no negative side effects and gives no systematic safety data.
Study notes · methods, sources and limitations
Participants or model 220 patients with endometrial cancer in the Tver report. 120 received adjunctive Imunofan, and the remainder formed the comparison group.
Design Intramuscular Imunofan before surgery, during radiotherapy and every six months during rehabilitation. Dose per injection, injection counts and allocation methods were not reported.
Important limitations
- The brief report omits treatment allocation, baseline prognosis, raw event counts and whether the percentage differences are absolute or relative. The survival observations cannot establish a causal effect. Venediktova also published a 2001 endometrial cancer report involving Imunofan and Tactivin. Participant overlap is unresolved, so the two reports should not be added as independent cohorts.
Palliative Medicine and Rehabilitation, 2004, issue 2, conference abstract II.13.62. · Original conference abstract
Animal research · 2004
Imunofan and immune measurements after acute chemical poisoning in rats
- Immune measurements
- Recovery of antibody formation, cytotoxicity, NK activity and delayed hypersensitivity described
- Lipid peroxidation
- Recovery of related laboratory measures described
The abstract describes recovery in T-dependent antibody formation, antibody-dependent cytotoxicity, natural-killer activity, delayed hypersensitivity and lipid-peroxidation measures after four days of Imunofan.
Study notes · methods, sources and limitations
Participants or model Wistar rats in four acute chemical-poisoning models.
Design Four days of Imunofan at 10 µg/kg after experimental acute chemical poisoning. Investigators measured antibody responses, cellular immune activity and lipid peroxidation.
Important limitations
- Group sizes, route, quantitative outcome values and adverse events are unavailable in the abstract. The experiment measured laboratory outcomes in poisoned rats. Human exposure protection was not studied.
- Numerical arm effects and a survival benefit cannot be determined from this abstract.
Experimental and Clinical Pharmacology. 2004;67(5):28–30. PMID 15559632. · Indexed abstract
Randomized study in people · 2009
[Using regulatory peptide imunofan in type 2 diabetes mellitus patients with diabetic foot syndrome].
- Clinical, laboratory and quality-of-life findings
- Reported improvement with adjunctive treatmentNo scores, response rates or confidence intervals in the indexed abstract
A randomized 69-person diabetic-foot comparison reported better clinical and immune outcomes with adjunctive Imunofan, but its abstract supplies no numerical treatment effect.
Study notes · methods, sources and limitations
Participants or model 69 people with type 2 diabetes and diabetic foot: 39 adjunctive Imunofan, 30 basic-care controls
Design Imunofan + basic therapy 39; basic therapy 30; type 2 diabetes with diabetic foot and retinal angiopathy.
- Randomized groups
- 39 adjunctive; 30 basic therapy
Important limitations
- The abstract provides no numerical treatment effect, concealment or blinding details; no claim of fewer amputations follows. Full methods, reporting completeness and independent replication remain to be appraised.
- Group sizes describe the design. They must not be presented as wound-healing rates or evidence of prevention of amputation.
Terapevticheskii arkhiv · PMID 20481041 · Original journal report
Comparison in people · 2025
[Effectiveness of local treatment of venous trophic ulcers in gerontological patients].
- Inflammatory activation at day 7
- More marked in adjunct groupsp<0.0083
- Cellular progression
- Leukocytes declined by day 15; reparative cytograms by day 22No numerical healing-rate or cell-count changes supplied
Groups receiving immune correction and/or optical irradiation showed differences in wound-cell patterns during combined care.
Study notes · methods, sources and limitations
Participants or model 281 older patients with venous ulcers across four treatment groups (74/69/69/69)
Design Four venous-ulcer groups: 74, 69, 69 and 69 elderly patients. Local therapy alone, plus Imunofan, plus optical irradiation, or both adjuncts. 0.1% polyhexanide-betaine gel for 7–10 days before Flamena.
Important limitations
- Cytological outcomes are surrogate measures; multiple concurrent interventions and unclear allocation limit causal attribution. Full methods, reporting completeness and independent replication remain to be appraised.
- Multiple local-treatment components and cytology outcomes; these are not Imunofan-only ulcer-healing effect sizes.
Khirurgiia · PMID 40785606 · Original journal report
Comparison in people · 2001
Use of tactivin and imunofan for the treatment of patients with endometrial carcinoma
Study of multiple preparations
- Radiation complications and immune measures
- Improvement reported with both agents; Imunofan described as more effective; numerical rates absent
Both adjunctive Tactivin and Imunofan were reported to reduce radiation complications and improve immune measures. The authors described Imunofan as somewhat more effective, without numerical rates.
Study notes · methods, sources and limitations
Participants or model Patients receiving complex treatment for endometrial adenocarcinoma; sample sizes not supplied in the indexed abstract.
Design Patients receiving complex treatment for endometrial adenocarcinoma; sample sizes not supplied in the indexed abstract.
Important limitations
- Group sizes, allocation details, complication counts and cancer-survival endpoints are unavailable. A 2004 Tver abstract by Gladkova and colleagues includes Venediktova as a coauthor. Participant overlap is unresolved.
Eksperimental'naia i klinicheskaia farmakologiia 2001 · Journal publication
Performance research in context
- Compound class
- Peptide research family
- Research collection
- Peptide bioregulation · editorial grouping
- Institutions in linked studies
- See individual study records
- Source review
- Review dates and the material assessed are listed with each publication below.
Understanding the evidence
Human research
69 people with type 2 diabetes and diabetic foot: 39 adjunctive Imunofan, 30 basic-care controls
Study methods
Study records describe the tested models, comparators and reported outcomes.
Independent replication
New citations are not automatically independent replication; shared programs and translated reports require cohort checks
Source access
New indexed primary abstracts and/or report reproductions linked; review depth shown per source
Safety evidence
Reported tolerability is not proof of safety; uncommon harms and long-term outcomes remain unresolved
Open a topic for the evidence assessment.
Patents and claimed inventions
These 3 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.
Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →
Findings by study
Comparison in people · 2009
Imunofan and skin infections in military cadets
A 150-cadet comparison reported 40 versus 133 skin infections per 1,000 during observation. CD4/CD8 ratios fell from 1.8 to 1.4 with Imunofan and from 1.6 to 0.9 in the comparison group.
Study notes and original source
Imunofan and skin infections in military cadets
G. G. Mar’in, V. G. Akimkin, V. A. Novikov, A. V. Tutel’yan, and colleagues · Military Medical Journal. 2009;330(9).
A 150-cadet comparison reported 40 versus 133 skin infections per 1,000 during observation. CD4/CD8 ratios fell from 1.8 to 1.4 with Imunofan and from 1.6 to 0.9 in the comparison group.
Results and tables
Reported findings and study design
The authors measured blood markers before dosing and at days 28–30 and tracked purulent skin infections. The companion conference report gives the incidence rates.
Population or model 150 male first-year cadets aged 18–21. Imunofan 75, no Imunofan 75, in the same training unit.
Dose, route and schedule
1 mL of 0.005% Imunofan solution (50 µg) intramuscularly once daily for three days. The comparison group lived and trained in the same conditions and did not receive the drug.
Protocol source ↗ · Original journal article and companion conference proceedings. The 2014 dissertation describes an expanded seasonal series.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Pyoderma incidence | 40 vs 133 per 1,000 | Imunofan versus comparison. The 75-per-group conference report supplies the rates. |
| Protection coefficient and effectiveness index | 69.2% and 3.25 | Values printed in the journal. Rounded incidence rates yield a slightly different ratio. |
| CD4/CD8 ratio at day 28–30 | 1.8 → 1.4 vs 1.6 → 0.9 | Imunofan versus comparison, based on the paper and conference report. |
Source for these results ↗ · Reviewed 2026-11-14
- Population / setting
- 150 male first-year cadets aged 18–21. Imunofan 75, no Imunofan 75, in the same training unit.
- Source reviewed
- Original journal article and companion conference proceedings. The 2014 dissertation describes an expanded seasonal series.
Study limitations
- The paper describes random group selection. Allocation concealment and masking are unclear.
- The matching methods and immune-marker values suggest the conference abstract repeats this sample and the 2014 thesis expands the program. No cohorts are added together.
Reviewed 2026-11-14.
Comparison in people · 2014
Imunofan infection prevention across two military training seasons
The dissertation reports author-calculated protection estimates of 61.5% in autumn and 56.3% in winter at three months. The treated group’s day-28 to day-30 skin bactericidal index was 80–90% compared with 60–70%.
Study notes and original source
Imunofan infection prevention across two military training seasons
G. G. Mar’in · Doctoral dissertation author abstract. Moscow, 2014. Tables 7 and 9.
The dissertation reports author-calculated protection estimates of 61.5% in autumn and 56.3% in winter at three months. The treated group’s day-28 to day-30 skin bactericidal index was 80–90% compared with 60–70%.
Results and tables
Reported findings and study design
The Moscow Military District prevention program followed training cohorts recruited around seasonal peaks. It tracked respiratory and skin illness and assessed blood markers after 28–30 days.
Population or model 162 Imunofan recipients and 165 comparison participants in the thesis immune-marker table. Other prevention cohorts had separate interventions.
Dose, route and schedule
1 mL of 0.005% Imunofan (50 µg) intramuscularly daily for three days, with follow-up for three months. The comparison groups did not receive Imunofan.
Protocol source ↗ · Author’s dissertation abstract, intervention methods and seasonal follow-up results.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Author-calculated pyoderma protection at month 3 | 61.5% autumn, 56.3% winter | From the author’s treated-versus-comparison incidence calculations. · Reported p<0.05 |
| Skin bactericidal index | 80–90% vs 60–70% | Imunofan versus untreated comparison. · Reported p<0.05 |
Source for these results ↗ · Reviewed 2026-11-14
- Population / setting
- 162 Imunofan recipients and 165 comparison participants in the thesis immune-marker table. Other prevention cohorts had separate interventions.
- Source reviewed
- Author’s dissertation abstract, intervention methods and seasonal follow-up results.
Study limitations
- Season, unit and concurrent prevention measures can influence infection rates. The thesis gives program results and a comparison table, with limited detail on allocation.
- This appears to extend the 2009 cadet study. The smaller group is excluded from any combined count.
Reviewed 2026-11-14.
Comparison in people · 2023
Imunofan in risk-stratified obstetric care: 112-woman program
The program reports threatened pregnancy loss falling from 41.3% to 19.6% and preterm birth from 8.7% to 4.7%. Imunofan was an adjunct only in the 36-woman middle-risk protocol; these overall results cannot be assigned to Imunofan.
Study notes and original source
Imunofan in risk-stratified obstetric care: 112-woman program
Imunofan adjunct to immunoglobulin in one risk stratum; not monotherapy · Original journal publication
Format: Original PDF · Reviewed: Original publisher PDF text, methods, Table 1 and discussion checked via indexed full text; numerical table not visually verified
N. Yu. Vladimirova, V. G. Nikitin, G. V. Chizhova · Healthcare of the Far East / Zdravookhranenie Dalnego Vostoka. 2023;(2):43–48
The program reports threatened pregnancy loss falling from 41.3% to 19.6% and preterm birth from 8.7% to 4.7%. Imunofan was an adjunct only in the 36-woman middle-risk protocol; these overall results cannot be assigned to Imunofan.
Results and tables
Reported findings and study design
Reported findings
The program reports threatened pregnancy loss falling from 41.3% to 19.6% and preterm birth from 8.7% to 4.7%. Imunofan was an adjunct only in the 36-woman middle-risk protocol; these overall results cannot be assigned to Imunofan.
Risk-stratified clinical program compared with earlier protocols; all groups received immunoglobulin, and the highest-risk group also plasmapheresis. Table 1 labels the n=112 dataset Nikitin 2017, although the article was published in 2023. No randomized Imunofan-only comparator.
Population or model 112 women with latent herpesvirus infection: low-risk n=27, renal-inflammatory disease n=36, prior reproductive loss n=49; historical cohorts n=24 and n=42 discussed separately
Dose, route and schedule
Imunofan intramuscularly in the medium-risk group, 2–4 weeks after completion of first-trimester immunoglobulin treatment. Immunoglobulin courses at weeks 8–12 and 20–24 in that group. Other risk groups followed different protocols; this is a historical bundled-care description.
Protocol source ↗ · Original publisher PDF text, methods, Table 1 and discussion checked via indexed full text; numerical table not visually verified
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Threatened pregnancy loss | 41.3% / 19.6% | Table’s without/after immunocorrection columns for the n=112 program; not the n=36 Imunofan subgroup · Table star: p<0.05 |
| Preterm birth | 8.7% / 4.7% | Same whole-program columns; raw event denominators not supplied · Table star: p<0.05 |
| Neonatal morbidity | 638.0 / 264.0 per 1,000 | Morbidity rate, not percentage of infants; multiple diagnoses may occur · Table star: p<0.05 |
| Viral transmission | 54.5% / 18.2% | No significance star for this row; narrative significance claims are broader than table notation |
| Neutral outcomes | No reduction in overall gestational complications or spontaneous pregnancy loss; no significant effect on perinatal mortality | Explicit discussion statement on printed p.47 |
Imunofan-specific effects cannot be isolated: different baseline risks, immunoglobulin exposure, plasmapheresis and historical comparisons confound the program outcomes. The 112 women are not an Imunofan treatment arm. Only the n=36 risk-group protocol explicitly adds it, and subgroup outcomes are not separately supplied. Publication year 2023 is not recruitment year: the outcome table labels these data 2017. No raw outcome counts, confidence intervals or systematic long-term child-safety follow-up were verified. The paper reports important neutral outcomes. Historical exposure does not establish a current indication or safety during pregnancy.
Source for these results ↗ · Reviewed 2026-11-08
- Population / setting
- 112 women with latent herpesvirus infection: low-risk n=27, renal-inflammatory disease n=36, prior reproductive loss n=49; historical cohorts n=24 and n=42 discussed separately
- Source reviewed
- Original publisher PDF text, methods, Table 1 and discussion checked via indexed full text; numerical table not visually verified
Study limitations
- Imunofan-specific effects cannot be isolated: different baseline risks, immunoglobulin exposure, plasmapheresis and historical comparisons confound the program outcomes.
- The 112 women are not an Imunofan treatment arm. Only the n=36 risk-group protocol explicitly adds it, and subgroup outcomes are not separately supplied.
- Publication year 2023 is not recruitment year: the outcome table labels these data 2017. No raw outcome counts, confidence intervals or systematic long-term child-safety follow-up were verified.
- The paper reports important neutral outcomes. Historical exposure does not establish a current indication or safety during pregnancy.
Reviewed 2026-11-08.
Review of earlier studies · 2026
From thymus extracts to synthetic thymomimetics
The review traces the move from thymus-derived mixtures to defined compounds and summarizes neutrophil phenotypes and functional assays reported for the thymopoietin-derived hexapeptide Imunofan.
Study notes and original source
From thymus extracts to synthetic thymomimetics
· Narrative review
I. V. Nesterova, L. V. Lomtatidze, G. A. Chudilova, S. V. Kovaleva, V. N. Chapurina, S. N. Pikturno · Adaptive Medical Immunology and Public Health Issues. 2026;2(1):6–19.
The review traces the move from thymus-derived mixtures to defined compounds and summarizes neutrophil phenotypes and functional assays reported for the thymopoietin-derived hexapeptide Imunofan.
Results and tables
Reported findings and study design
Findings described in words
Population or model Review of laboratory and clinical literature on thymic peptides.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Thymomimetic research | The authors summarize evidence from different thymic compounds and discuss changes in neutrophil phenotype and function in studies of Imunofan. |
Secondary synthesis. No new clinical cohort or pooled effect estimate.
Source for these results ↗ · Reviewed 2026-11-10
- Population / setting
- Review of laboratory and clinical literature on thymic peptides.
- Source reviewed
- Original Russian review and cited evidence types checked. The review does not present a new controlled trial or pooled estimate.
Study limitations
- Cell markers, laboratory findings and outcomes from combination care answer different questions. The review does not validate efficacy across thymic peptides.
Reviewed 2026-11-10.
Comparison in people · 2011
Imunofan and mixed herpesvirus infections in Redkin and Lyuboshenko’s 2011 comparison
The paper reports clinical improvement in 73.7% with Imunofan-based care versus 57.1% with a pooled thymic-peptide comparison. Immunogram normalization was similar (85.7% versus 84.3%). Allocation followed the order patients presented, and some percentages do not match the stated counts.
Study notes and original source
Imunofan and mixed herpesvirus infections in Redkin and Lyuboshenko’s 2011 comparison
· Original journal article
Y. V. Redkin, T. M. Lyuboshenko · Public Health of the Far East. 2011;3(49):38–41.
The paper reports clinical improvement in 73.7% with Imunofan-based care versus 57.1% with a pooled thymic-peptide comparison. Immunogram normalization was similar (85.7% versus 84.3%). Allocation followed the order patients presented, and some percentages do not match the stated counts.
Results and tables
Reported findings and study design
The methods list 35 patients per group but also give 29 women and 8 men in the Imunofan arm. Assignment followed order of presentation. Both groups received individualized care. The comparator pooled Thymalin, Thymogen and Tactivin. Lymphocyte markers and IFN-γ were assessed before and after treatment.
Population or model Adults with chronic recurrent infections referred to an immunologist in Omsk in 2010–2011. The methods give 35 patients per group, but list 29 women and 8 men in the Imunofan arm (37) and 25 women and 10 men in the comparison arm (35).
Dose, route and schedule
The paper reports 1 mL intramuscularly every three days for 10–15 injections. Its printed concentration differs from the product labeling, so the amount of active peptide per injection cannot be confirmed from this report.
Protocol source ↗ · Original methods, p. 40
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Clinical improvement | 73.7% versus 57.1% | Imunofan-based care versus the pooled thymic-peptide group. Denominators conflict in the paper. |
| Fewer, shorter or no recurrences | 36.8% versus 28.6% | Composite reported in Table 2. |
| Immunogram normalization | 85.7% versus 84.3% | Table 2. No formal between-group test given for these percentages. |
| Temperature normalization | 21% versus 14.3% | |
| Lower antiviral or antibacterial antibody titres | 31.6% versus 14.3% | |
| CD3 lymphocytes | 53.34 ± 1.55% to 65.8 ± 1.70% | Within the Imunofan group. · Reported p < 0.05 |
| CD4 lymphocytes | 31.36 ± 1.29% to 36.95 ± 1.40% | Within the Imunofan group. · Reported p < 0.05 |
| Spontaneous IFN-γ | 23.8 ± 2.47 to 42.13 ± 7.75 pg/mL | Within the Imunofan group. · Reported p < 0.05 |
| Stimulated IFN-γ | 1,669.7 ± 123.1 to 2,170.6 ± 89.8 pg/mL | Within the Imunofan group. · Reported p < 0.05 |
The Table 2 percentages are reproduced as published. The paper gives conflicting group sizes and no event counts, and the groups received different care. The IFN-γ and lymphocyte figures are within-group changes.
Source for these results ↗ · Reviewed 2026-11-10
- Population / setting
- Adults with chronic recurrent infections referred to an immunologist in Omsk in 2010–2011. The methods give 35 patients per group, but list 29 women and 8 men in the Imunofan arm (37) and 25 women and 10 men in the comparison arm (35).
- Source reviewed
- Original issue PDF, pp. 38–41, including both tables and the methods.
Study limitations
- The comparison group pooled Thymalin, Thymogen and Tactivin. The paper gives no drug-specific subgroup outcomes, so the rates cannot establish a difference versus any one preparation.
- The groups were assigned in order of presentation and differed in average age. Concurrent antimicrobial and immune-active treatment varied by clinical presentation.
- The Imunofan denominator conflicts within the methods, and Table 2 supplies percentages without event counts or a separate significance test. No systematic adverse-event results were reported.
Reviewed 2026-11-10.
Comparison in people · 2022
Imunofan after surgery for acute peritonitis in children
For diffuse peritonitis, median ICU stay was 2 versus 4 days in groups of 5 and 3 children. The authors also reported changes in neutrophil populations and function. The groups were small and random assignment was not documented.
ICU stay in diffuse peritonitis · 2 (1.0–2.5) versus 4 (3.5–4.0) days · Imunofan plus standard care (n = 5) versus standard care (n = 3). Medians and reported intervals. · Reported p < 0.05
Study notes and original source
Imunofan after surgery for acute peritonitis in children
· Original journal article, author-shared copy
I. V. Nesterova, G. A. Chudilova, V. N. Chapurina, S. V. Kovaleva, Yu. V. Teterin, N. K. Barova, D. E. Lyagusha, V. A. Tarakanov · Medical Immunology (Russia). 2022;24(3):553–572.
For diffuse peritonitis, median ICU stay was 2 versus 4 days in groups of 5 and 3 children. The authors also reported changes in neutrophil populations and function. The groups were small and random assignment was not documented.
Results and tables
Reported findings and study design
In local peritonitis, 7 children received the adjunct and 3 received standard care. In diffuse disease, the groups had 5 and 3 children. Another 18 healthy children provided laboratory reference values. The investigators used blood flow cytometry to measure neutrophil subsets and tested phagocytosis and oxidative-burst activity before and after treatment.
Population or model 18 children aged 5–12 with acute peritonitis after surgery. Local disease: 7 received Imunofan plus standard care and 3 received standard care. Diffuse disease: 5 and 3, respectively. Another 18 healthy children provided laboratory reference values.
Dose, route and schedule
Both groups received postoperative standard care. The Imunofan groups received 1 mL intramuscularly on five consecutive days, then on alternate days, for six injections in local disease and ten in diffuse disease. The figure’s concentration unit conflicts with the injectable product label.
Protocol source ↗ · Original journal article, Figure 2
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| ICU stay in diffuse peritonitis | 2 (1.0–2.5) versus 4 (3.5–4.0) days | Imunofan plus standard care (n = 5) versus standard care (n = 3). Medians and reported intervals. · Reported p < 0.05 |
| CD64-positive neutrophil subset in diffuse disease | 60.7% to 0.74% | Within the Imunofan arm. Standard-care subgroup showed no significant change on this measure. · Within-arm p < 0.05 |
| Time to fever normalization in diffuse disease | 4 (3.0–4.5) versus 6 (5.5–6.5) days | Imunofan plus standard care (n = 5) versus standard care (n = 3). · Reported p < 0.05 |
| Drain removal in diffuse disease | 3 (2–3) versus 5 (4.5–5.0) days | Reported p < 0.05 |
| CD64-negative neutrophil subset in diffuse disease | 29.6% to 95.97% | Within the Imunofan arm. Standard-care endpoint was 40.1%. Healthy reference median was 93.3%. · Within-arm p < 0.05 |
| Actively phagocytosing neutrophils in diffuse disease | 62% to 71% | Within the Imunofan arm. · Reported p < 0.05 |
| Stimulated oxidative-burst assay in local disease | 7.5% to 17.0% formazan-positive cells | Within the Imunofan arm. The separate cytochemical index changed from 0.46 to 0.49 (p > 0.05). · Reported p < 0.05 for cell percentage |
| Local disease: phagocytosis and digestive activity | Several changes did not reach statistical significance | The authors report p > 0.05 for the actively phagocytosing cell fraction, digestive activity and particle uptake in the Imunofan arm. |
The ICU comparison rests on eight children, and the marker results include changes from baseline. The study does not establish a reliable clinical treatment effect.
Source for these results ↗ · Reviewed 2026-11-10
- Population / setting
- 18 children aged 5–12 with acute peritonitis after surgery. Local disease: 7 received Imunofan plus standard care and 3 received standard care. Diffuse disease: 5 and 3, respectively. Another 18 healthy children provided laboratory reference values.
- Source reviewed
- Original article methods, clinical results, Figures 2–6 and selected neutrophil assays. The 2022 companion reports identical treatment-group sizes and repeats key outcomes.
Study limitations
- The clinical groups had only 3–7 children each. The study does not describe random assignment or blinded outcome assessment.
- The paper reports bowel paresis in 80% of the diffuse comparison group, but lists three patients in that group. The percentage has no reconcilable event count.
- The related 2022 Effective Pharmacotherapy article repeats the same arm sizes, clinical timings and several marker values. Its patient counts are not added as a separate cohort.
- Figure 2 prints a concentration unit that conflicts with the product insert. The administered peptide mass is unconfirmed.
Reviewed 2026-11-10.
Laboratory analysis · 2003
Imunofan ranked differently across two antioxidant assays
Imunofan ranked near the bottom in the lipid assay, alongside glycine. It ranked third in the aqueous assay, below ginseng extract and the thymopoietin II fragment.
Study notes and original source
Imunofan ranked differently across two antioxidant assays
· Original laboratory study, indexed abstract
A. V. Tutel’yan, G. I. Klebanov, S. E. Il’ina, O. B. Lyubitskii · Bulletin of Experimental Biology and Medicine. 2003;136(2):155–158. PMID 14631497.
Imunofan ranked near the bottom in the lipid assay, alongside glycine. It ranked third in the aqueous assay, below ginseng extract and the thymopoietin II fragment.
Results and tables
Reported findings and study design
One assay measured lipid oxidation in phospholipid liposomes. The other measured luminol oxidation in aqueous solution.
Population or model Two cell-free oxidation assays comparing Imunofan, other peptides, glycine and Siberian ginseng extract.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Lipid peroxyl radical assay | Ginseng extract > bursin > cyclobursin > thymopoietin II fragment > Imunofan and glycine | |
| Aqueous peroxyl and luminol radical assay | Ginseng extract > thymopoietin II fragment > Imunofan > glycine, cyclobursin and bursin |
Source for these results ↗ · Reviewed 2026-11-10
- Population / setting
- Two cell-free oxidation assays comparing Imunofan, other peptides, glycine and Siberian ginseng extract.
- Source reviewed
- Original indexed abstract. The ranking is reported separately for each assay.
Study limitations
- The abstract gives the order of activity without numerical effect sizes or uncertainty. These cell-free comparisons do not measure antioxidant effects in patients.
Reviewed 2026-11-10.
Cited in a dissertation · 2002
Imunofan, Thymalin and levamisole in a historical schizophrenia citation
Palko’s dissertation cites positive responses of 53.6% for Imunofan, 43.8% for Thymalin and 34% for levamisole. The original comparison and its response definition have not been verified.
Study notes and original source
Imunofan, Thymalin and levamisole in a historical schizophrenia citation
· Secondary dissertation citation
A. P. Muzychenko and colleagues, as cited by O. L. Palko · 2002 comparison cited in O. L. Palko’s dissertation on myelopeptide immunomodulators.
Palko’s dissertation cites positive responses of 53.6% for Imunofan, 43.8% for Thymalin and 34% for levamisole. The original comparison and its response definition have not been verified.
Results and tables
Reported findings and study design
Population or model Patients described as having treatment-resistant schizophrenia. Group sizes are unavailable in the cited passage.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Positive response as quoted in the dissertation | 53.6% Imunofan, 43.8% Thymalin, 34% levamisole | Group sizes, definitions and statistical tests are unavailable. |
The bibliography entry points to milnacipran. The percentages are traceable to Palko’s text, but the original comparison has not been verified.
Source for these results ↗ · Reviewed 2026-11-10
- Population / setting
- Patients described as having treatment-resistant schizophrenia. Group sizes are unavailable in the cited passage.
- Source reviewed
- Palko’s dissertation text and reference 36. Other bibliographies identify a 2002 Lipetsk monograph by Muzychenko, Dmitrenkov, Zakhatsky and Barzakov as a possible source. The comparison pages remain unavailable.
Study limitations
- Palko attributes the figures to Muzychenko et al. (2002), but the bibliography entry under that attribution lists a paper about milnacipran (Ixel).
- The passage gives no group sizes, doses, allocation, response definition, statistical tests or harms. The 1998 Thymalin conference report and the Imunofan patent describe different sets of arms. Their methods cannot be assigned to this comparison.
Reviewed 2026-11-10.
Comparison in people · 2004
Imunofan alongside multimodal breast cancer treatment in Samara
Local postoperative complications · 20/92 (21.7%) with Imunofan versus 24/82 (29.3%) with standard care, calculated from the reported counts. The printed p<0.01 does not agree with a simple comparison of those counts.
Study notes and original source
Imunofan alongside multimodal breast cancer treatment in Samara
· Original dissertation author abstract
T. G. Zolotareva · Candidate dissertation author abstract, Samara State Medical University, defended in Ufa, 2004.
Local postoperative complications · 20/92 (21.7%) with Imunofan versus 24/82 (29.3%) with standard care, calculated from the reported counts. The printed p<0.01 does not agree with a simple comparison of those counts.
Results and tables
Reported findings and study design
Reported findings
The author abstract reports 50 µg (1 mL of 0.005% solution) intramuscularly daily for five days, in three courses after radiotherapy, after mastectomy and between chemotherapy cycles two and three. Total reported exposure was 750 µg.
Population or model 174 patients with breast cancer treated in Samara from 2001 to 2003, 92 with adjunctive Imunofan and 82 controls.
Dose, route and schedule
The author abstract reports 50 µg (1 mL of 0.005% solution) intramuscularly daily for five days, in three courses after radiotherapy, after mastectomy and between chemotherapy cycles two and three. Total reported exposure was 750 µg.
Protocol source ↗ · Author abstract methods, Table 1 and the stage IIIA clinical results.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Local postoperative complications | 20/92 (21.7%) with Imunofan versus 24/82 (29.3%) with standard care, calculated from the reported counts. The printed p<0.01 does not agree with a simple comparison of those counts. | |
| Lymph drainage lasting over 10 days | 16/92 (17.4%) versus 19/82 (23.2%), calculated from the reported counts. | |
| Wound suppuration | 2/92 versus 2/82. The author abstract describes no clear overall difference in wound complications. | |
| Stage IIIA leukopenia during chemotherapy | 3/20 versus 6/19, reported in the stage-specific comparison. |
Randomization and blinded assessment were not reported. The author abstract gives inconsistent percentages, subgroup denominators and significance statements. Differences in treatment tolerance cannot establish tumor control or survival benefit.
Source for these results ↗ · Reviewed 2026-11-14
- Population / setting
- 174 patients with breast cancer treated in Samara from 2001 to 2003, 92 with adjunctive Imunofan and 82 controls.
- Source reviewed
- Author abstract methods, Table 1 and the stage IIIA clinical results.
Study limitations
- Randomization and blinded assessment were not reported. The author abstract gives inconsistent percentages, subgroup denominators and significance statements. Differences in treatment tolerance cannot establish tumor control or survival benefit.
Reviewed 2026-11-14.
Animal research · 2013
Imunofan pretreatment and mammary tumor growth in mice
Tumor diameter at week 9 among tumor-bearing mice · 14.1 mm with Imunofan versus 6.9 mm with saline (p=0.029). The IL-2 group measured 13.9 mm (p=0.092 versus saline).
Study notes and original source
Imunofan pretreatment and mammary tumor growth in mice
· Original conference report
E. V. Moiseeva, S. G. Semushina, D. A. Aronov, A. N. Murashev, A. M. Shishkin, V. K. Bozhenko · Modern High Technologies, 2013, issue 9, p. 54.
Tumor diameter at week 9 among tumor-bearing mice · 14.1 mm with Imunofan versus 6.9 mm with saline (p=0.029). The IL-2 group measured 13.9 mm (p=0.092 versus saline).
Results and tables
Reported findings and study design
Reported findings
One injection before tumor-cell implantation. Imunofan was reported as 0.2 mL of a 1% solution, IL-2 as 1,000 IU, and saline as 0.2 mL of 0.9% NaCl per mouse. Three days later, mice received 500,000 syngeneic mammary tumor cells subcutaneously. Tumor appearance and diameter were tracked weekly through week 15.
Population or model 33 male A/Sn mice. Imunofan n=10, IL-2 n=11 and saline n=12.
Dose, route and schedule
One injection before tumor-cell implantation. Imunofan was reported as 0.2 mL of a 1% solution, IL-2 as 1,000 IU, and saline as 0.2 mL of 0.9% NaCl per mouse. Three days later, mice received 500,000 syngeneic mammary tumor cells subcutaneously. Tumor appearance and diameter were tracked weekly through week 15.
Protocol source ↗ · Original proceedings report, methods and Tables 1–2.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Tumor diameter at week 9 among tumor-bearing mice | 14.1 mm with Imunofan versus 6.9 mm with saline (p=0.029). The IL-2 group measured 13.9 mm (p=0.092 versus saline). | |
| Palpable tumors by week 8 | 70% with Imunofan, 73% with IL-2 and 50% with saline. | |
| Deaths among tumor-bearing mice through week 15 | 100% with Imunofan, 75% with IL-2 and 40% with saline, as reported. The denominators are the animals that developed tumors. | |
| Palpable tumors by week 15 | 70% with Imunofan, 73% with IL-2 and 83% with saline. Earlier detection and faster growth among tumor bearers occurred alongside a lower final proportion with palpable tumors in the treated arms. |
Selected tumor measurements and outcomes
| Outcome | Imunofan | IL-2 | Saline |
|---|---|---|---|
| Assigned | 10 | 11 | 12 |
| Palpable tumor by week 8 | 70% | 73% | 50% |
| Palpable tumor by week 15 | 70% | 73% | 83% |
| Tumor diameter, week 9 | 14.1 mm | 13.9 mm | 6.9 mm |
| Deaths among tumor bearers, week 15 | 100% | 75% | 40% |
The comparison used a small pre-implantation model. The diameter and mortality comparisons were conditional on developing a tumor. The report gives unadjusted tests at several time points and does not provide evidence on human tumor growth or survival. The report prints a 1% solution without clarifying the formulation or injection route for the pretreatment. The actual peptide mass cannot be confirmed.
Source for these results ↗ · Reviewed 2026-11-14
- Population / setting
- 33 male A/Sn mice. Imunofan n=10, IL-2 n=11 and saline n=12.
- Source reviewed
- Original proceedings report, methods and Tables 1–2.
Study limitations
- The comparison used a small pre-implantation model. The diameter and mortality comparisons were conditional on developing a tumor. The report gives unadjusted tests at several time points and does not provide evidence on human tumor growth or survival.
- The report prints a 1% solution without clarifying the formulation or injection route for the pretreatment. The actual peptide mass cannot be confirmed.
Reviewed 2026-11-14.
Lab research · 2015
Imunofan increased growth measures in mouse mammary tumor cultures
BALB/c tumor and lymph-node cultures · Treated wells had more cells on day 7 (p<0.01). Tumor cultures had more growth clusters on day 14 (p<0.05). Absolute counts were not reported.
Study notes and original source
Imunofan increased growth measures in mouse mammary tumor cultures
· Original conference abstract
D. A. Aronov, N. V. Antipova, T. D. Petrova, D. Ch. Sultanov, S. G. Semushina, E. V. Moiseeva · 27th Winter Youth Scientific School, Moscow, 9–12 February 2015, p. 8.
BALB/c tumor and lymph-node cultures · Treated wells had more cells on day 7 (p<0.01). Tumor cultures had more growth clusters on day 14 (p<0.05). Absolute counts were not reported.
Results and tables
Reported findings and study design
Reported findings
Imunofan at reported dilutions from 1:10 to 1:10,000 versus untreated cultures. Investigators counted adherent cells and clusters larger than 10 cells and assessed viability with trypan blue.
Population or model Short-term mouse mammary tumor, spleen and regional lymph-node cultures. Numbers of mice and replicates are unavailable.
Dose, route and schedule
Imunofan at reported dilutions from 1:10 to 1:10,000 versus untreated cultures. Investigators counted adherent cells and clusters larger than 10 cells and assessed viability with trypan blue.
Protocol source ↗ · Original proceedings abstract. Author names follow the abstract text.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| BALB/c tumor and lymph-node cultures | Treated wells had more cells on day 7 (p<0.01). Tumor cultures had more growth clusters on day 14 (p<0.05). Absolute counts were not reported. | |
| Other mouse cultures | The authors reported similar trends and higher splenocyte viability in one strain. |
The cultures contained multiple cell types. The abstract does not show whether the growth signal came from cancer cells directly or from other cells in the culture. The cited animal work is background, distinct from the culture outcomes reported here.
Source for these results ↗ · Reviewed 2026-11-14
- Population / setting
- Short-term mouse mammary tumor, spleen and regional lymph-node cultures. Numbers of mice and replicates are unavailable.
- Source reviewed
- Original proceedings abstract. Author names follow the abstract text.
Study limitations
- The cultures contained multiple cell types. The abstract does not show whether the growth signal came from cancer cells directly or from other cells in the culture. The cited animal work is background, distinct from the culture outcomes reported here.
Reviewed 2026-11-14.
Comparison in people · 2004
Imunofan during endometrial cancer treatment and rehabilitation
Radiation complications · Reported 12.7% lower with Imunofan (p<0.05). Absolute rates and the denominator for this difference were not supplied.
Study notes and original source
Imunofan during endometrial cancer treatment and rehabilitation
· Original conference abstract
N. N. Gladkova, M. A. Demidova, M. G. Venediktova · Palliative Medicine and Rehabilitation, 2004, issue 2, conference abstract II.13.62.
Radiation complications · Reported 12.7% lower with Imunofan (p<0.05). Absolute rates and the denominator for this difference were not supplied.
Results and tables
Reported findings and study design
Reported findings
Intramuscular Imunofan before surgery, during radiotherapy and every six months during rehabilitation. Dose per injection, injection counts and allocation methods were not reported.
Population or model 220 patients with endometrial cancer in the Tver report. 120 received adjunctive Imunofan, and the remainder formed the comparison group.
Dose, route and schedule
Intramuscular Imunofan before surgery, during radiotherapy and every six months during rehabilitation. Dose per injection, injection counts and allocation methods were not reported.
Protocol source ↗ · Original conference abstract II.13.62. Its figures are not assigned to the 2001 Venediktova journal report.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Radiation complications | Reported 12.7% lower with Imunofan (p<0.05). Absolute rates and the denominator for this difference were not supplied. | |
| Karnofsky performance assessment | The proportion with high scores was reported as 21.8% higher (p<0.05). Absolute rates and the threshold for a high score were unavailable. | |
| Mortality and survival | The authors reported one-year mortality 9.8% lower and a trend toward 8% higher five-year survival. Event counts, uncertainty and an adjusted comparison were unavailable. | |
| Lymphocyte recovery and tolerability | Reported about 1.5 times faster lymphocyte recovery (p<0.05). The abstract states no negative side effects and gives no systematic safety data. |
The brief report omits treatment allocation, baseline prognosis, raw event counts and whether the percentage differences are absolute or relative. The survival observations cannot establish a causal effect. Venediktova also published a 2001 endometrial cancer report involving Imunofan and Tactivin. Participant overlap is unresolved, so the two reports should not be added as independent cohorts.
Source for these results ↗ · Reviewed 2026-11-14
- Population / setting
- 220 patients with endometrial cancer in the Tver report. 120 received adjunctive Imunofan, and the remainder formed the comparison group.
- Source reviewed
- Original conference abstract II.13.62. Its figures are not assigned to the 2001 Venediktova journal report.
Study limitations
- The brief report omits treatment allocation, baseline prognosis, raw event counts and whether the percentage differences are absolute or relative. The survival observations cannot establish a causal effect.
- Venediktova also published a 2001 endometrial cancer report involving Imunofan and Tactivin. Participant overlap is unresolved, so the two reports should not be added as independent cohorts.
Reviewed 2026-11-14.
Randomized study in people · 2011
Imunofan-containing regimens after lung cancer surgery
Postoperative purulent-inflammatory complications · The authors reported lower frequency and severity, especially with the Imunofan combinations. The available abstract provides no event counts, effect sizes or dosing.
Study notes and original source
Imunofan-containing regimens after lung cancer surgery
· Original journal abstract
E. R. Nemtsova, T. A. Karmakova, O. A. Bezborodova, V. V. Skripnik, A. M. Amiraliev, A. V. Sobolev, O. V. Pikin, N. V. Edeleva, R. I. Yakubovskaya, V. I. Chissov · Russian Journal of Oncology 16(4), 24–30.
Postoperative purulent-inflammatory complications · The authors reported lower frequency and severity, especially with the Imunofan combinations. The available abstract provides no event counts, effect sizes or dosing.
Results and tables
Reported findings and study design
Reported findings
The authors describe randomized comparison arms for two antioxidants (laprot and ceruloplasmin) combined with either Imunofan or Galavit, plus a control group.
Dose, route and schedule
The authors describe randomized comparison arms for two antioxidants (laprot and ceruloplasmin) combined with either Imunofan or Galavit, plus a control group.
Protocol source ↗ · Original publisher abstract and arm sizes.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Postoperative purulent-inflammatory complications | The authors reported lower frequency and severity, especially with the Imunofan combinations. The available abstract provides no event counts, effect sizes or dosing. | |
| Group sizes | Laprot + Imunofan 31, ceruloplasmin + Imunofan 18, laprot + Galavit 28, ceruloplasmin + Galavit 24 and control 47. |
There was no Imunofan-only arm. The accessible abstract gives no treatment schedule, detailed outcomes or allocation procedures. The endpoint concerns recovery after surgery.
Source for these results ↗ · Reviewed 2026-11-14
- Population / setting
- 148 patients in five arms following surgery for lung malignancies. 49 received an Imunofan-containing combination.
- Source reviewed
- Original publisher abstract and arm sizes.
Study limitations
- There was no Imunofan-only arm. The accessible abstract gives no treatment schedule, detailed outcomes or allocation procedures. The endpoint concerns recovery after surgery.
Reviewed 2026-11-14.
Animal research · 2004
Imunofan and immune measurements after acute chemical poisoning in rats
The abstract describes recovery in T-dependent antibody formation, antibody-dependent cytotoxicity, natural-killer activity, delayed hypersensitivity and lipid-peroxidation measures after four days of Imunofan.
Study notes and original source
Imunofan and immune measurements after acute chemical poisoning in rats
P. F. Zabrodskii, V. G. Germanchuk, M. L. Nodel, O. A. Vasilenko, A. N. Aredakov · Experimental and Clinical Pharmacology. 2004;67(5):28–30. PMID 15559632.
The abstract describes recovery in T-dependent antibody formation, antibody-dependent cytotoxicity, natural-killer activity, delayed hypersensitivity and lipid-peroxidation measures after four days of Imunofan.
Results and tables
Reported findings and study design
Findings described in words
Four days of Imunofan at 10 µg/kg after experimental acute chemical poisoning. Investigators measured antibody responses, cellular immune activity and lipid peroxidation.
Population or model Wistar rats in four acute chemical-poisoning models.
Dose, route and schedule
The abstract reports Imunofan at 10 µg/kg for four days. The administration route is unspecified.
Protocol source ↗ · Original indexed abstract
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Immune measurements | Recovery of antibody formation, cytotoxicity, NK activity and delayed hypersensitivity described | |
| Lipid peroxidation | Recovery of related laboratory measures described |
Numerical arm effects and a survival benefit cannot be determined from this abstract.
Source for these results ↗ · Reviewed 2026-11-11
- Population / setting
- Wistar rats in four acute chemical-poisoning models.
- Source reviewed
- Original indexed abstract checked.
Study limitations
- Group sizes, route, quantitative outcome values and adverse events are unavailable in the abstract.
- The experiment measured laboratory outcomes in poisoned rats. Human exposure protection was not studied.
Reviewed 2026-11-11.
Experiment described in a patent · 2006
Imunofan alongside multimodal breast cancer treatment — RU2270693C2
The patent describes two breast cancer cases in which T-cell measures rose during combined treatment. Both were reported free of recognized recurrence or metastasis at the 12-month examination.
Case 2, CD3 and CD4 cells · CD3-positive cells went from 520 to 1,700 cells/mm³ and CD4-positive cells from 290 to 590 cells/mm³ by the end of multimodal treatment.
Study notes and original source
Imunofan alongside multimodal breast cancer treatment — RU2270693C2
Patent-defined substance or composition · Patent publication
Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
S. V. Kozlov, T. G. Zolotareva · RU2270693C2 · patent family 35844500
The patent describes two breast cancer cases in which T-cell measures rose during combined treatment. Both were reported free of recognized recurrence or metastasis at the 12-month examination.
Results and tables
Reported patent results
Reported findings
The patent describes two breast cancer cases in which T-cell measures rose during combined treatment. Both were reported free of recognized recurrence or metastasis at the 12-month examination.
Two patients aged 39 and 46 with stage IIB and IIIB breast cancer, respectively. Both received cancer care plus three five-day IM Imunofan courses. The Russian description and claim specify 0.005%, 1 mL daily. The abstract gives 0.05%, a conflicting concentration.
Population or model Two patients aged 39 and 46 with stage IIB and IIIB breast cancer, respectively. Both received cancer care plus three five-day IM Imunofan courses. The Russian description and claim specify 0.005%, 1 mL daily. The abstract gives 0.05%, a conflicting concentration.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Case 2, CD3 and CD4 cells | CD3-positive cells went from 520 to 1,700 cells/mm³ and CD4-positive cells from 290 to 590 cells/mm³ by the end of multimodal treatment. | |
| Case follow-up | The patent reports no recurrence or metastasis detected at 12 months in either illustrative case. |
These two examples supply no comparator or estimate of attributable benefit. Whether either case was part of the Samara dissertation cohort is unresolved.
Source for these results ↗ · Reviewed 2026-11-14
- Population / setting
- Two patients aged 39 and 46 with stage IIB and IIIB breast cancer, respectively. Both received cancer care plus three five-day IM Imunofan courses. The Russian description and claim specify 0.005%, 1 mL daily. The abstract gives 0.05%, a conflicting concentration.
- Source reviewed
- Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
- Two uncontrolled cases received radiotherapy, surgery and chemotherapy. A related 174-patient Samara author abstract describes the same regimen and shares an investigator. The case histories may be part of that program.
- These two examples supply no comparator or estimate of attributable benefit. Whether either case was part of the Samara dissertation cohort is unresolved.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Reviewed 2026-11-14.
Experiment described in a patent · 2010
Imunofan: adjunctive steroid-resistance claim — RU2404792C1
A reported rheumatoid-arthritis/uveitis case improved during combined treatment, with immunological changes and an eight-month remission.
Illustrative case: inflammatory markers · ESR 40 → 5; ocular autoantibody titer 1:512 → 1:128 · Before/after combined treatment; not a controlled comparison · After the course
Study notes and original source
Imunofan: adjunctive steroid-resistance claim — RU2404792C1
Patent-defined substance or composition · Patent publication
Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Василий Вячеславович Лебедев (RU), Василий Вячеславович Лебедев, Татьяна Владимировна Величко (RU), Татьяна Владимировна Величко · RU2404792C1 · patent family 44057532
A reported rheumatoid-arthritis/uveitis case improved during combined treatment, with immunological changes and an eight-month remission.
Results and tables
Reported patent results
Reported findings
A reported rheumatoid-arthritis/uveitis case improved during combined treatment, with immunological changes and an eight-month remission.
Patent clinical case examples of adjunctive Imunofan in steroid-resistant inflammatory eye disease; earlier literature is cited separately.
Population or model Patent clinical case examples of adjunctive Imunofan in steroid-resistant inflammatory eye disease; earlier literature is cited separately.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Illustrative case: inflammatory markers | ESR 40 → 5; ocular autoantibody titer 1:512 → 1:128 | Before/after combined treatment; not a controlled comparison · After the course |
| Illustrative case: visual acuity | Right eye improved to 0.9; left eye to 0.02 | Post-treatment values; do not interpret as change scores without the baseline · After the course |
| Follow-up | Remission for more than 8 months; later relapses reported 2–3 times/year | Subsequent courses and concurrent medicines complicate attribution |
The patent also cites earlier 38% and 75% remission claims; those are background research, not a newly randomized cohort in this patent. Selected combined-care examples do not establish reversal of steroid resistance.
Source for these results ↗ · Reviewed 2026-11-06
- Population / setting
- Patent clinical case examples of adjunctive Imunofan in steroid-resistant inflammatory eye disease; earlier literature is cited separately.
- Source reviewed
- Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
- An adjunctive method claim does not establish generalized immune tolerance or autoimmune disease-modifying efficacy.
- The patent also cites earlier 38% and 75% remission claims; those are background research, not a newly randomized cohort in this patent. Selected combined-care examples do not establish reversal of steroid resistance.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Reviewed 2026-11-06.
Experiment described in a patent · 2003
Imunofan as adjunctive treatment for negative symptoms in schizophrenia — RU2195957C2
The patent reports a positive outcome in 20 of 33 patients (60.6%). It describes no comparator.
Study notes and original source
Imunofan as adjunctive treatment for negative symptoms in schizophrenia — RU2195957C2
Patent-defined substance or composition · Patent publication
Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
V. V. Barzakov, A. P. Muzychenko, S. I. Dmitrenkov · RU2195957C2 · patent family 20242171
The patent reports a positive outcome in 20 of 33 patients (60.6%). It describes no comparator.
Results and tables
Reported patent results
Reported findings
The patent reports a positive outcome in 20 of 33 patients (60.6%). It describes no comparator.
Patent case series in people with schizophrenia and negative symptoms. Psychotropic medication continued. The specification describes 1 mL of 0.005% Imunofan intramuscularly daily for 15 days.
Population or model Patent case series in people with schizophrenia and negative symptoms. Psychotropic medication continued. The specification describes 1 mL of 0.005% Imunofan intramuscularly daily for 15 days.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Reported positive outcome | 20/33 (60.6%) | Patent case series. No standardized response definition, comparator or uncertainty estimate. |
| Illustrative case at six months | The authors describe improved social and occupational function. | Single case example while on continuing psychiatric treatment. |
| Adverse effects | None reported in the specification. | The filing does not describe systematic safety monitoring. |
The filing gives no controlled estimate of Imunofan’s effect. Its relationship to Muzychenko’s 2002 comparison is unknown, so the reports cannot be pooled.
Source for these results ↗ · Reviewed 2026-11-10
- Population / setting
- Patent case series in people with schizophrenia and negative symptoms. Psychotropic medication continued. The specification describes 1 mL of 0.005% Imunofan intramuscularly daily for 15 days.
- Source reviewed
- Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
- The patent describes an uncontrolled series. Overlap with the 2002 comparison cited in a separate dissertation is unresolved.
- The filing gives no controlled estimate of Imunofan’s effect. Its relationship to Muzychenko’s 2002 comparison is unknown, so the reports cannot be pooled.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Reviewed 2026-11-10.
Review of earlier studies · 1999
[Imunofan: new-generation synthetic peptide agent]
The review discusses TNF, IL-6 and redox responses alongside immune-stimulating effects in other disease settings.
Study notes and original source
[Imunofan: new-generation synthetic peptide agent]
Lebedev VV, Pokrovskiĭ VI · Vestnik Rossiiskoi akademii meditsinskikh nauk
The review discusses TNF, IL-6 and redox responses alongside immune-stimulating effects in other disease settings.
- Population / setting
- Narrative review of peptide development and clinical applications
- Source reviewed
- Original publication abstract checked; full methodological appraisal pending.
Study limitations
- This is a review rather than a controlled autoimmune trial.
- Anti-inflammatory markers do not demonstrate immune tolerance or disease modification.
Reviewed 2026-11-05.
Comparison in people · 2001
Use of tactivin and imunofan for the treatment of patients with endometrial carcinoma
Both adjunctive Tactivin and Imunofan were reported to reduce radiation complications and improve immune measures. The authors described Imunofan as somewhat more effective, without numerical rates.
Study notes and original source
Use of tactivin and imunofan for the treatment of patients with endometrial carcinoma
Tactivin tissue extract and synthetic Imunofan as separate comparisons · Journal publication
Venediktova MG · Eksperimental'naia i klinicheskaia farmakologiia 2001
Both adjunctive Tactivin and Imunofan were reported to reduce radiation complications and improve immune measures. The authors described Imunofan as somewhat more effective, without numerical rates.
Results and tables
Reported findings and study design
Both adjunctive Tactivin and Imunofan were reported to reduce radiation complications and improve immune measures. The authors described Imunofan as somewhat more effective, without numerical rates.
Patients receiving complex treatment for endometrial adenocarcinoma; sample sizes not supplied in the indexed abstract.
Population or model Patients receiving complex treatment for endometrial adenocarcinoma; sample sizes not supplied in the indexed abstract.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Radiation complications and immune measures | Improvement reported with both agents; Imunofan described as more effective; numerical rates absent |
Group sizes, allocation details, complication counts and cancer-survival endpoints are unavailable. A 2004 Tver abstract by Gladkova and colleagues includes Venediktova as a coauthor. Participant overlap is unresolved.
Source for these results ↗ · Reviewed 2026-11-01
- Population / setting
- Patients receiving complex treatment for endometrial adenocarcinoma; sample sizes not supplied in the indexed abstract.
- Source reviewed
- Original-publication metadata and indexed abstract checked in Europe PMC. No unavailable full-text figures inferred.
Study limitations
- Group sizes, allocation details, complication counts and cancer-survival endpoints are unavailable. A 2004 Tver abstract by Gladkova and colleagues includes Venediktova as a coauthor. Participant overlap is unresolved.
Reviewed 2026-11-01.
Randomized study in people · 2009
[Using regulatory peptide imunofan in type 2 diabetes mellitus patients with diabetic foot syndrome].
A randomized 69-person diabetic-foot comparison reported better clinical and immune outcomes with adjunctive Imunofan, but its abstract supplies no numerical treatment effect.
Study notes and original source
[Using regulatory peptide imunofan in type 2 diabetes mellitus patients with diabetic foot syndrome].
· Original journal report
Tutel'ian AV, Iakubovskaia IA, Skrypnik NV, Levedev VV · Terapevticheskii arkhiv · PMID 20481041
A randomized 69-person diabetic-foot comparison reported better clinical and immune outcomes with adjunctive Imunofan, but its abstract supplies no numerical treatment effect.
Results and tables
Reported findings and study design
A randomized 69-person diabetic-foot comparison reported better clinical and immune outcomes with adjunctive Imunofan, but its abstract supplies no numerical treatment effect.
Imunofan + basic therapy 39; basic therapy 30; type 2 diabetes with diabetic foot and retinal angiopathy.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Clinical, laboratory and quality-of-life findings | Reported improvement with adjunctive treatment | No scores, response rates or confidence intervals in the indexed abstract |
| Randomized groups | 39 adjunctive; 30 basic therapy |
Group sizes describe the design. They must not be presented as wound-healing rates or evidence of prevention of amputation.
Source for these results ↗ · Reviewed 2026-11-01
- Population / setting
- 69 people with type 2 diabetes and diabetic foot: 39 adjunctive Imunofan, 30 basic-care controls
- Source reviewed
- Primary citation and indexed abstract reviewed through Europe PMC. Full article not appraised.
Study limitations
- The abstract provides no numerical treatment effect, concealment or blinding details; no claim of fewer amputations follows.
- Full methods, reporting completeness and independent replication remain to be appraised.
Reviewed 2026-11-01.
Comparison in people · 2025
[Effectiveness of local treatment of venous trophic ulcers in gerontological patients].
Groups receiving immune correction and/or optical irradiation showed differences in wound-cell patterns during combined care.
Study notes and original source
[Effectiveness of local treatment of venous trophic ulcers in gerontological patients].
· Original journal report
Kuznetsov MR, Matveev DV, Abduvosidov KA, Chudnykh SM, Matveev SD, Snitsar AV, Yasnopolskaya NV, Pyatykh MV · Khirurgiia · PMID 40785606
Groups receiving immune correction and/or optical irradiation showed differences in wound-cell patterns during combined care.
Results and tables
Reported findings and study design
Four venous-ulcer groups: 74, 69, 69 and 69 elderly patients. Local therapy alone, plus Imunofan, plus optical irradiation, or both adjuncts. 0.1% polyhexanide-betaine gel for 7–10 days before Flamena.
Population or model 281 older patients with venous ulcers across four treatment groups (74/69/69/69)
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Inflammatory activation at day 7 | More marked in adjunct groups | p<0.0083 |
| Cellular progression | Leukocytes declined by day 15; reparative cytograms by day 22 | No numerical healing-rate or cell-count changes supplied |
Multiple local-treatment components and cytology outcomes; these are not Imunofan-only ulcer-healing effect sizes.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- 281 older patients with venous ulcers across four treatment groups (74/69/69/69)
- Source reviewed
- Primary citation and indexed abstract reviewed through Europe PMC. Full article not appraised.
Study limitations
- Cytological outcomes are surrogate measures; multiple concurrent interventions and unclear allocation limit causal attribution.
- Full methods, reporting completeness and independent replication remain to be appraised.
Reviewed 2026-10-05.
Animal research · 2003
Nociceptive reactions during stimulation of immunity in rats with different individual sensitivities to stress.
Imunofan suppressed active behavior and increased pain sensitivity, with larger hyperalgesia in stress-sensitive rats.
Study notes and original source
Nociceptive reactions during stimulation of immunity in rats with different individual sensitivities to stress.
· Original journal report
Abramov YB, Kozlov AY, Sinel'shchikova OS, Torgovanova GV · Neuroscience and behavioral physiology · PMID 14635999
Imunofan suppressed active behavior and increased pain sensitivity, with larger hyperalgesia in stress-sensitive rats.
Results and tables
Reported findings and study design
43 male Wistar rats; IM Imunofan 10 microliters of 0.005% solution; separate intracerebroventricular experiment.
Population or model 43 male Wistar rats differing in stress sensitivity
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Pain thresholds | Lower: hyperalgesia reported | More marked in stress-sensitive rats; no numerical threshold shift supplied |
| Open-field behavior | Active behavior suppressed |
Values describe this study and its comparison. Unreported effect sizes and missing denominators have not been inferred.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- 43 male Wistar rats differing in stress sensitivity
- Source reviewed
- Primary citation and indexed abstract reviewed through Europe PMC. Full article not appraised.
Study limitations
- Animal route-specific effects cannot predict human adverse-event rates; this translation is not separate replication of the earlier Russian report.
- Full methods, reporting completeness and independent replication remain to be appraised.
Reviewed 2026-10-05.
Animal research · 2020
Imunofan-RDKVYR Peptide-Stimulates Skin Cell Proliferation and Promotes Tissue Repair.
RDKVYR increased proliferation in cultured skin cells and modestly improved ear-pinna repair in mice. The paper calls it Imunofan/Thymohexin; older RKDVYR records must not be silently merged with this sequence.
Fibroblast proliferation · 30–40% increase · p<0.05
Study notes and original source
Imunofan-RDKVYR Peptide-Stimulates Skin Cell Proliferation and Promotes Tissue Repair.
Sawicka J, Dzierżyńska M, Wardowska A, Deptuła M, Rogujski P, Sosnowski P, Filipowicz N, Mieczkowska A, Sass P, Pawlik A, Hać A, Schumacher A, Gucwa M, Karska N, Kamińska J, Płatek R, Mazuryk J, Zieliński J, Kondej K, Młynarz P, Mucha P, Skowron P, Janus Ł, Herman-Antosiewicz A, Sachadyn P, Czupryn A, Piotrowski A, Pikuła M, Rodziewicz-Motowidło S · Molecules (Basel, Switzerland)
RDKVYR increased proliferation in cultured skin cells and modestly improved ear-pinna repair in mice. The paper calls it Imunofan/Thymohexin; older RKDVYR records must not be silently merged with this sequence.
Results and tables
Reported findings and study design
Imunofan laboratory assays in human fibroblasts, keratinocytes and donor-derived stem cells, plus mouse ear-injury model.
Population or model Human skin-cell cultures and mice
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Fibroblast proliferation | 30–40% increase | p<0.05 |
| Keratinocyte proliferation | 20–50% increase | p<0.05 |
| Mouse repair, BALB/c | 8% versus control | |
| Mouse repair, C57BL/6 | 36% versus control | |
| DNA-demethylation gene activity | Increase reported | p<0.05 |
Cell growth and mouse ear repair are separate experiments. No human wound-healing percentage is established.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- Human skin-cell cultures and mice
- Source reviewed
- Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Study limitations
- Preclinical study, not a human wound-healing trial.
- RDKVYR differs from the RKDVYR spelling in older Thymohexin literature; preparation equivalence is unresolved.
Reviewed 2026-10-05.
Related compound research
Follow shared publications or research classes. These links do not establish equivalent effects between compounds.
Research collection curated by @PepMariner · editorial standards. Send a source correction ↗
Browse bibliography & PDFs ↗